Please use this identifier to cite or link to this item: https://hdl.handle.net/10137/5203
Email LibraryRMU.DOH@nt.gov.au to ask for this document in a different format
Title: Bisphosphonate guidelines for treatment and prevention of myeloma bone disease.
Authors: Lee, Oi Lin
Horvath, Noemi
Lee, Cindy
Joshua, Doug
Ho, Joy
Szer, Jeff
Quach, Hang
Spencer, Andrew
Harrison, Simon
Mollee, Peter
Roberts, Andrew W
Talaulikar, Dipti
Brown, Ross
Augustson, Bradley
Ling, Silvia
Jaksic, Wilfrid
Gibson, John
Kalff, Anna
Johnston, Anna
Kalro, Akash
Ward, Chris
Prince, H Miles
Zannettino, Andrew
Citation: Internal medicine journal 2017-08; 47(8): 938-951
Abstract: Multiple myeloma (MM) is a haematological malignancy characterised by the clonal proliferation of plasma cells in the bone marrow. More than 80% of patients with MM display evidence of myeloma bone disease (MBD), characterised by the formation of osteolytic lesions throughout the axial and appendicular skeleton. MBD significantly increases the risk of skeletal-related events such as pathologic fracture, spinal cord compression and hypercalcaemia. MBD is the result of MM plasma cells-mediated activation of osteoclast activity and suppression of osteoblast activity. Bisphosphonates (BP), pyrophosphate analogues with high bone affinity, are the only pharmacological agents currently recommended for the treatment and prevention of MBD and remain the standard of care. Pamidronate and zoledronic acid are the most commonly used BP to treat MBD. Although generally safe, frequent high doses of BP are associated with adverse events such as renal toxicity and osteonecrosis of the jaw. As such, optimal duration and dosing of BP therapy is required in order to minimise BP-associated adverse events. The following guidelines provide currently available evidence for the adoption of a tailored approach when using BP for the management of MBD.
Click to open PubMed article: https://www.ezpdhcs.nt.gov.au/login?url=https://www.ncbi.nlm.nih.gov/pubmed/28782211
Click to open Pubmed Article: https://www.ezpdhcs.nt.gov.au/login?url=https://www.ncbi.nlm.nih.gov/pubmed/28782211
Journal title: Internal medicine journal
Publication Date: 2017-08
Type: Journal Article
URI: https://hdl.handle.net/10137/5203
DOI: 10.1111/imj.13502
metadata.dc.identifier.orcid: http://orcid.org/0000-0001-6783-2301
http://orcid.org/0000-0002-6646-6167
Appears in Collections:(a) NT Health Research Collection

Files in This Item:
There are no files associated with this item.


Items in ePublications are protected by copyright, with all rights reserved, unless otherwise indicated.